Why is Eli Lilly using non-GAAP financial measures?

Eli Lilly uses non-GAAP financial measures to provide investors with a clearer view of its ongoing operational performance. These measures exclude items that are highly variable, difficult to predict, and can significantly impact reported results, such as in-process R&D charges and restructuring costs. The company believes these adjustments help in making more meaningful period-over-period comparisons and identifying underlying operational trends.

What specific one-time charges were excluded from the Q1 2011 and Q1 2010 results?

For Q1 2011, excluded items included in-process research and development charges related to the diabetes collaboration with Boehringer Ingelheim and restructuring charges for severance costs. For Q1 2010, excluded items were in-process research and development charges from an in-licensing transaction with Acrux and restructuring charges.

Did the filing mention the impact of U.S. healthcare reform?

Yes, the filing states that Eli Lilly quantified the impact of U.S. healthcare reform on its first-quarter 2011 results and included its estimated impact in the company's 2011 financial expectations.

LLY 8-K: Earnings & Results

Summary

Eli Lilly and Company (LLY) filed an 8-K on April 18, 2011, to report its first-quarter 2011 financial results. The report highlights the company's use of non-GAAP financial measures to provide a clearer view of ongoing operations, excluding significant one-time items such as in-process research and development (IPR&D) charges and restructuring costs. These adjustments aim to offer investors a more meaningful comparison of performance between periods and insight into operational trends.

Key Highlights

1Eli Lilly reported its Q1 2011 financial results via press release and investor teleconference.
2The company utilized non-GAAP financial measures (e.g., non-GAAP net income, EPS) for reporting, excluding specific one-time charges.
3Excluded items for Q1 2011 included IPR&D charges from the Boehringer Ingelheim diabetes collaboration and restructuring charges.
4Excluded items for Q1 2010 included IPR&D charges from an Acrux in-licensing transaction and restructuring charges.
5The report quantified the impact of foreign exchange rates and U.S. healthcare reform on Q1 2011 results.
6Lilly provided 2011 financial expectations, including both GAAP and non-GAAP earnings per share guidance, considering the impact of U.S. healthcare reform.

ELI LILLY & Co 8-K Report, Financial Results (Apr 18, 2011)

Summary

Key Highlights

Frequently Asked Questions